This company has been acquired
OptiNose Management
Management criteria checks 2/4
OptiNose's CEO is Ramy Mahmoud, appointed in Jan 2023, has a tenure of 2.33 years. total yearly compensation is $4.70M, comprised of 15.2% salary and 84.8% bonuses, including company stock and options. directly owns 0.34% of the company’s shares, worth $331.72K. The average tenure of the management team and the board of directors is 2.7 years and 3.4 years respectively.
Key information
Ramy Mahmoud
Chief executive officer
US$4.7m
Total compensation
| CEO salary percentage | 15.18% |
| CEO tenure | 2.3yrs |
| CEO ownership | 0.3% |
| Management average tenure | 2.7yrs |
| Board average tenure | 3.4yrs |
Recent management updates
Recent updates
Improved Prescription Fulfillment And Primary Care Entry Will Unlock Opportunity
Enhanced sales force execution and improved prescription fulfillment processes are expected to drive revenue growth through better market penetration.Further Upside For OptiNose, Inc. (NASDAQ:OPTN) Shares Could Introduce Price Risks After 56% Bounce
The OptiNose, Inc. ( NASDAQ:OPTN ) share price has done very well over the last month, posting an excellent gain of...OptiNose, Inc. (NASDAQ:OPTN) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny
To the annoyance of some shareholders, OptiNose, Inc. ( NASDAQ:OPTN ) shares are down a considerable 29% in the last...OptiNose, Inc. (NASDAQ:OPTN) Might Not Be As Mispriced As It Looks After Plunging 31%
Unfortunately for some shareholders, the OptiNose, Inc. ( NASDAQ:OPTN ) share price has dived 31% in the last thirty...Earnings Release: Here's Why Analysts Cut Their OptiNose, Inc. (NASDAQ:OPTN) Price Target To US$3.50
One of the biggest stories of last week was how OptiNose, Inc. ( NASDAQ:OPTN ) shares plunged 42% in the week since its...Slammed 34% OptiNose, Inc. (NASDAQ:OPTN) Screens Well Here But There Might Be A Catch
OptiNose, Inc. ( NASDAQ:OPTN ) shareholders that were waiting for something to happen have been dealt a blow with a 34...Market Cool On OptiNose, Inc.'s (NASDAQ:OPTN) Revenues Pushing Shares 30% Lower
OptiNose, Inc. ( NASDAQ:OPTN ) shareholders won't be pleased to see that the share price has had a very rough month...Not Many Are Piling Into OptiNose, Inc. (NASDAQ:OPTN) Stock Yet As It Plummets 42%
The OptiNose, Inc. ( NASDAQ:OPTN ) share price has fared very poorly over the last month, falling by a substantial 42...There's Reason For Concern Over OptiNose, Inc.'s (NASDAQ:OPTN) Massive 32% Price Jump
OptiNose, Inc. ( NASDAQ:OPTN ) shares have continued their recent momentum with a 32% gain in the last month alone. But...Revenues Working Against OptiNose, Inc.'s (NASDAQ:OPTN) Share Price
You may think that with a price-to-sales (or "P/S") ratio of 2.1x OptiNose, Inc. ( NASDAQ:OPTN ) is a stock worth...OptiNose, Inc. (NASDAQ:OPTN) Might Not Be As Mispriced As It Looks After Plunging 29%
OptiNose, Inc. ( NASDAQ:OPTN ) shareholders won't be pleased to see that the share price has had a very rough month...The Consensus EPS Estimates For OptiNose, Inc. (NASDAQ:OPTN) Just Fell Dramatically
The latest analyst coverage could presage a bad day for OptiNose, Inc. ( NASDAQ:OPTN ), with the analysts making...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$30m |
| Dec 31 2024 | US$5m | US$713k | -US$22m |
| Sep 30 2024 | n/a | n/a | -US$31m |
| Jun 30 2024 | n/a | n/a | -US$41m |
| Mar 31 2024 | n/a | n/a | -US$31m |
| Dec 31 2023 | US$2m | US$647k | -US$35m |
| Sep 30 2023 | n/a | n/a | -US$41m |
| Jun 30 2023 | n/a | n/a | -US$46m |
| Mar 31 2023 | n/a | n/a | -US$68m |
| Dec 31 2022 | US$1m | US$504k | -US$75m |
| Sep 30 2022 | n/a | n/a | -US$75m |
| Jun 30 2022 | n/a | n/a | -US$77m |
| Mar 31 2022 | n/a | n/a | -US$82m |
| Dec 31 2021 | US$1m | US$504k | -US$82m |
| Sep 30 2021 | n/a | n/a | -US$91m |
| Jun 30 2021 | n/a | n/a | -US$95m |
| Mar 31 2021 | n/a | n/a | -US$97m |
| Dec 31 2020 | US$2m | US$489k | -US$100m |
| Sep 30 2020 | n/a | n/a | -US$101m |
| Jun 30 2020 | n/a | n/a | -US$109m |
| Mar 31 2020 | n/a | n/a | -US$110m |
| Dec 31 2019 | US$1m | US$475k | -US$110m |
| Sep 30 2019 | n/a | n/a | -US$111m |
| Jun 30 2019 | n/a | n/a | -US$108m |
| Mar 31 2019 | n/a | n/a | -US$105m |
| Dec 31 2018 | US$609k | US$451k | -US$107m |
Compensation vs Market: Ramy's total compensation ($USD4.70M) is above average for companies of similar size in the US market ($USD647.92K).
Compensation vs Earnings: Ramy's compensation has increased whilst the company is unprofitable.
CEO
Ramy Mahmoud (59 yo)
Dr. Ramy A. Mahmoud, M.D., M.P.H., serves as Chief Executive Officer and Director of OptiNose US Inc. since January 2023. He serves as Chief Executive Officer & Director of OptiNose, Inc. since January 31,...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.3yrs | US$4.70m | 0.34% $ 331.7k | |
| Chief Legal Officer & Corporate Secretary | 8.3yrs | US$1.99m | 0.19% $ 189.6k | |
| Chief Commercial Officer | 2.4yrs | US$1.85m | 0.029% $ 29.0k | |
| Chief Financial Officer | less than a year | no data | no data | |
| VP of Finance & Chief Accounting Officer | 2.9yrs | no data | 0.0033% $ 3.2k | |
| Vice President of Investor Relations & Business Development | no data | no data | no data | |
| Chief Human Resources Officer & VP of Human Resources | 7.3yrs | no data | no data |
Experienced Management: OPTN's management team is considered experienced (2.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.3yrs | US$4.70m | 0.34% $ 331.7k | |
| Independent Director | 7.3yrs | US$112.62k | 0% $ 0 | |
| Independent Chairman | 3.1yrs | US$157.12k | 0% $ 0 | |
| Independent Director | 3.4yrs | US$97.62k | 0% $ 0 | |
| Independent Director | 7.6yrs | US$110.12k | 0% $ 0 | |
| Independent Director | 4.4yrs | US$112.62k | 0% $ 0 | |
| Independent Director | 3.4yrs | US$100.12k | 0% $ 0 |
Experienced Board: OPTN's board of directors are considered experienced (3.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/20 01:25 |
| End of Day Share Price | 2025/05/20 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
OptiNose, Inc. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gary Nachman | BMO Capital Markets Equity Research |
| Glen Santangelo | Jefferies LLC |
| David Steinberg | Jefferies LLC |